An open label positron emission tomography [PET] study in healthy male subjects to investigate brain dopamine D3 occupancy kinetics, pharmacokinetics and safety of single oral doses of GSK598809, using [11C]-(+)-PHNO as PET ligand
Phase of Trial: Phase I
Latest Information Update: 20 May 2009
At a glance
- Drugs GSK 598809 (Primary)
- Indications Drug abuse; Eating disorders; Smoking withdrawal
- Focus Pharmacokinetics
- 11 May 2007 New trial record.